ArticleClinical outcome of lapatinib and capecitabine in Her-2 +ve advanced/ metastatic breast cancer patients: A prospective study
ArticleClinical outcome of lapatinib and capecitabine in Her-2 +ve advanced/ metastatic breast cancer patients: A prospective study
ArticleEfficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients
ArticleEfficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients
ArticleAssessment of The Efficacy of Trastuzumab as Adjuvant Chemotherapy in Correlation with Clinicopathological Features in Patients with Her/2neu Positive Breast Cancer Attending Suez
ArticleAssessment of The Efficacy of Trastuzumab as Adjuvant Chemotherapy in Correlation with Clinicopathological Features in Patients with Her/2neu Positive Breast Cancer Attending Suez
ArticleAdded Metformin to Systematic Neoadjuvant Chemotherapy in Breast Cancer Patients: Randomized Study from Egypt
ArticleAdded Metformin to Systematic Neoadjuvant Chemotherapy in Breast Cancer Patients: Randomized Study from Egypt
ArticleFrequency and Clinical Features of Over-Expressed HER2 in Egyptian Breast Cancer Women Patients
ArticleFrequency and Clinical Features of Over-Expressed HER2 in Egyptian Breast Cancer Women Patients
ArticleGeriatric Assessment in Elderly Cancer Patients Receiving Chemotherapy in Ain Shams University Hospital: An Implementation Study
ArticleGeriatric Assessment in Elderly Cancer Patients Receiving Chemotherapy in Ain Shams University Hospital: An Implementation Study
ArticleClinicopathological Characteristics and Survival of Triple-Negative Breast Cancer Patients: A single Institution Study from Egypt
ArticleClinicopathological Characteristics and Survival of Triple-Negative Breast Cancer Patients: A single Institution Study from Egypt
ArticleThe validity of giving adjuvant capecitabine after standard anthracycline and/or taxanes based neo-/adjuvant chemotherapy in early triple-negative breast cancer patients: An Egypt
ArticleThe validity of giving adjuvant capecitabine after standard anthracycline and/or taxanes based neo-/adjuvant chemotherapy in early triple-negative breast cancer patients: An Egypt